<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01206088</url>
  </required_header>
  <id_info>
    <org_study_id>CAMN107AKR02</org_study_id>
    <nct_id>NCT01206088</nct_id>
  </id_info>
  <brief_title>Tasigna in Glivec-resistant or Intolerant Patients in CML</brief_title>
  <official_title>A Phase IV Study for Nilotinib in Patients With Imatinib-resistant or Intolerant Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Chronic or Accelerated Phase.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of nilotinib in patients with&#xD;
      Imatinib resistant or intolerant CML-CP or AC. Efficacy evaluation will be made by Complete&#xD;
      cytogenetic response rate(CCyR) at 12 months after nilotinib administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete cytogenetic response (CCyR) rate</measure>
    <time_frame>at 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of safety by NCI-CTCAE version 3.0</measure>
    <time_frame>until 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>CML</condition>
  <condition>Nilotinib</condition>
  <condition>Imatinib Resistant</condition>
  <condition>Imatinib Intolerant</condition>
  <arm_group>
    <arm_group_label>nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nilotinib</intervention_name>
    <description>administration of nilotinib as 2nd line</description>
    <arm_group_label>nilotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Imatinib resistant chronic myelogenous leukemia in chronic phase with cytogenetic&#xD;
             confirmation of Philadelphia chromosome.&#xD;
&#xD;
          -  Documented chronic phase CML as defined by:&#xD;
&#xD;
               -  &lt; 15% blasts in peripheral blood and bone marrow&#xD;
&#xD;
               -  &lt; 30% blasts plus promyelocytes in peripheral blood and bone marrow&#xD;
&#xD;
               -  &lt; 20% basophils in the peripheral blood&#xD;
&#xD;
               -  ≥ 100 x 109/L (≥ 100,000 /mm3) platelets&#xD;
&#xD;
               -  No evidence of extramedullary leukemic involvement, with the exception of&#xD;
                  hepatosplenomegaly&#xD;
&#xD;
               -  the patients with no CHR(complete hematologic response) after 3 months treatment,&#xD;
                  no mimical cytogenetic response(Ph+&lt;65%) after 6 months treatment, no major&#xD;
                  cytogenetic response(Ph+&lt;35%) after 12 months treatment.&#xD;
&#xD;
        Or&#xD;
&#xD;
          -  Imatinib resistant Philadelphia positive CML-AC will be defined as at lease one&#xD;
             following and no bast crisis before treatment.&#xD;
&#xD;
               -  &lt;30% and ≥ 15% blasts in peripheral blood and bone marrow&#xD;
&#xD;
               -  ≥ 30% blasts plus promyelocytes in peripheral blood and bone marrow&#xD;
&#xD;
               -  ≥ 20% basophils in the peripheral blood&#xD;
&#xD;
               -  &lt; 100 x 109/L (≥ 100,000 /mm3) platelets without related treatment&#xD;
&#xD;
               -  progression of CML-AP with Imatinib treatment, no hematologic response in bone&#xD;
                  marrow after at least 4 weeks treatment with imatinib. Progression from AP will&#xD;
                  be defined by increased numbers more than 50% of peripheral WBCs, blasts,&#xD;
                  basophils and platelets.&#xD;
&#xD;
          -  definition of Imatinib intolerance in CML-CP and AP&#xD;
&#xD;
               -  the patients who discontinued imatinib treatment with any dosage due to Grade 3&#xD;
                  or 4 non-hematologic adverse event or Grade 4 hematologic adverse event sustained&#xD;
                  for more than 7 days even best complementary therapy.&#xD;
&#xD;
          -  WHO performance scale ≤ 2&#xD;
&#xD;
          -  provide signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac dysfunction : LVEF &lt;45% by echocardiography, using pacemaker,Congenital long&#xD;
             QT syndrome or a known family history of long QT syndrome, History of or presence of&#xD;
             clinically significant ventricular or atrial tachyarrhythmias, Clinically significant&#xD;
             resting brachycardia (&lt;50 beats per minute),QTc &gt; 450 msec on baseline ECG (using the&#xD;
             QTcF formula), Myocardial infarction within 12 months prior to starting study, Other&#xD;
             clinically significant heart disease (e.g. unstable angina, congestive heart failure&#xD;
             or uncontrolled hypertension).&#xD;
&#xD;
          -  Known cytopathologically confirmed CNS infiltration (in absence of suspicion of CNS&#xD;
             involvement, lumbar puncture not required).&#xD;
&#xD;
          -  Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or&#xD;
             uncontrolled infection).&#xD;
&#xD;
          -  History of significant congenital or acquired bleeding disorder unrelated to cancer.&#xD;
&#xD;
          -  Treatment with any CSGF within 1 week of Day 1 except Erythropoietin.&#xD;
&#xD;
          -  History of non-compliance to medical regimens or inability to grant consent.&#xD;
&#xD;
          -  Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon)&#xD;
&#xD;
          -  Patients with another primary malignancy except if the other primary malignancy is&#xD;
             neither currently clinically significant or requiring active intervention&#xD;
&#xD;
          -  Patients actively receiving therapy with strong CYP3A4 inhibitors (e.g, erythromycin,&#xD;
             ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir,&#xD;
             mibefradil) and the treatment cannot be either discontinued or switched to a different&#xD;
             medication prior to starting study drug. See link for complete list of these&#xD;
             medications: http://medicine.iupui.edu/flockhart/table.htm.. Novartis must be&#xD;
             contacted if a patient needs to be started on any of these drugs during study&#xD;
             treatment.&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea,&#xD;
             vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass&#xD;
             surgery)&#xD;
&#xD;
          -  History of acute pancreatitis within 1 year of study entry or past medical history of&#xD;
             chronic pancreatitis.&#xD;
&#xD;
          -  patients who diagnosed HIV infection.&#xD;
&#xD;
          -  patients who has hypersensitivity for nilotinib or its additives&#xD;
&#xD;
          -  Patients who are currently receiving treatment with any medications that have the&#xD;
             potential to prolong the QT interval and the treatment cannot be either discontinued&#xD;
             or switched to a different medication prior to starting study drug (Please see&#xD;
             http://www.torsades.org/medical-pros/drug-lists/printable-drug-list.cfm for a&#xD;
             comprehensive list of agents that prolong the QT interval)&#xD;
&#xD;
          -  Patients who are: (a) pregnant, (b) breast feeding, (c) of childbearing potential&#xD;
             without a negative pregnancy test prior to baseline and (d) male or female of&#xD;
             childbearing potential unwilling to use contraceptive precautions throughout the trial&#xD;
&#xD;
          -  Patients with rare genetic disease such as galactose intolerance, moderate lactase&#xD;
             deficiency or glucose-galactose absorption disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Mary hospital, Catholic medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>September 20, 2010</study_first_submitted>
  <study_first_submitted_qc>September 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2010</study_first_posted>
  <last_update_submitted>February 24, 2017</last_update_submitted>
  <last_update_submitted_qc>February 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

